Testicular Neoplasms Clinical Trial
Official title:
GAMEC-SHORT (S) & GAMEC-ANTHRACYCLINE(A) (Combination Chemotherapy With GCSF, Actinomycin-D, Methotrexate, Etoposide and Cisplatin) Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)
St Bartholomew's hospital completed a study using the regimen GAMEC (PEG-filgrastim, actinomycin-D, methotrexate, etoposide, cisplatin). The results of this study showed that 50% of patients with relapsed testicular cancer could be cured using this treatment. These results are very encouraging and compare very favourably to other treatment protocols. In reviewing this study, it became clear that of the 5 cycles of treatment which were proposed, the first 3 seemed to matter and the last 2 did not appear important. In addition there was a group of patients who appeared to do particularly well namely patients under the age of 35 and those who had a normal LDH (lactate dehydrogenase). LDH is a blood test which monitors cancer activity. Selecting patients which fill both these criteria, this trial aims to see whether the investigators can maintain the good results the investigators have seen but using only 3 cycles of treatment. This will therefore shorten the treatment from 10 weeks to 6 weeks, thus reducing the side effects.
GAMEC-II (GAMEC -S & GAMEC-A) is an open-labelled, non-randomised clinical trial in patients with relapsed germ cell tumours (GCT) and its objectives are: 1. To establish the response rates to GAMEC-S or GAMEC-A 2. To establish the safety and efficacy of substitution of epirubicin for etoposide (GAMEC-A regimen) 3. To establish the toxicity of GAMEC-A 4. To establish progression free survival (PFS) 5. To establish whether shortening GAMEC-S in patients without adverse prognostic factors reduces toxicity without compromising survival. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00231582 -
High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II
|
Phase 2 | |
| Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
| Terminated |
NCT02577172 -
Testicular Cancer and Aerobic and Strength Training
|
N/A | |
| Completed |
NCT03403777 -
Avelumab in Refractory Testicular Germ Cell Cancer.
|
Phase 2 | |
| Completed |
NCT02890030 -
The Platinum Study Comparison Group
|
||
| Recruiting |
NCT05264337 -
Lymphedema After Urologic Surgery
|
||
| Active, not recruiting |
NCT03426865 -
Role of Axumin PET Scan in Germ Cell Tumor
|
||
| Completed |
NCT00001270 -
Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma
|
Phase 1 | |
| Completed |
NCT02459132 -
High-Intensity Aerobic Interval Training in Testicular Cancer Survivors
|
N/A | |
| Terminated |
NCT02499952 -
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
|
Phase 2 | |
| Recruiting |
NCT02304575 -
Quality of Life Among Testicular Cancer Survivors
|
N/A | |
| Withdrawn |
NCT02492360 -
Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy
|
N/A | |
| Completed |
NCT04122430 -
Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumours
|
||
| Recruiting |
NCT02229916 -
Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS
|
||
| Completed |
NCT02161692 -
Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors
|
Phase 2 | |
| Completed |
NCT02966509 -
Engagement of Patients With Advanced Cancer
|
N/A | |
| Recruiting |
NCT02341989 -
Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
|
Phase 3 | |
| Completed |
NCT05056688 -
Effect of Online Education Given to Young Adults on Testicular Cancer Health Beliefs and Behaviors
|
N/A | |
| Terminated |
NCT05229900 -
A Study of SGN-ALPV in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00123773 -
Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence
|
Phase 2 |